Nuwellis (NUWE) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,415,021 on September 16, 2025, based on Application No. 18/298,860. The patent relates to the use of one or more hemolysis sensors with extracorporeal blood filtration systems-such as ultrafiltration therapy and continuous renal replacement therapy-to help detect and localize red blood cell destruction occurring within or around the circuit. The intellectual property supports Nuwellis’ pediatric device, Vivian, in development and future platform innovation.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUWE:
- Nuwellis Secures NIH Grant for Pediatric Device Development
- Nuwellis announces NIH awarded $3M multi-year grant to KBT
- Nuwellis introduces 24-hour circuit for Aquadex therapy in the U.S.
- Nuwellis Announces At The Market Offering Agreement
- Nuwellis, Inc. Earnings Call: Challenges and Strategic Initiatives